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Abstract
Mutations in the transmembrane activator and calcium-modulating cyclophilin ligand interactor
(TACI) were previously found to be associated with hypogammaglobulinemia in humans. It has
been shown that proliferation inducing ligand (APRIL) elicits class switch recombination (CSR)
by inducing recruitment of MyD88 to a TACI highly conserved cytoplasmic domain (THC). We
have identified a patient with hypogammaglobulinemia carrying a missense mutation (S231R)
predicted to affect the THC. Aiming to evaluate the relevance of this novel mutation of TACI in
CSR induction, we tested the ability of TACI, TLR9, or/and CD40 ligands to trigger CSR in naive
B cells and B-cell lines carrying S231R. IgG secretion was impaired when triggered by TACI or/
and TLR9 ligands on S231R-naive B cells. Likewise, these stimuli induced less expression of
activation-induced cytidine deaminase, I(γ)1-C(μ), and I(γ)1-C(μ), while induction by optimal
CD40 stimulation was indistinguishable from controls. These cells also showed an impaired
cooperation between TACI and TLR9 pathways, as well as a lack of APRIL-mediated
enhancement of CD40 activation in suboptimal conditions. Finally, after APRIL ligation, S231R-
mutated TACI failed to colocalize with MyD88. Collectively, these results highlight the
requirement of an intact MyD88-binding site in TACI to trigger CSR.
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Introduction
Antibody diversification is critical for the generation of immune protection [1]. B cells
emerging from the bone marrow mature and pursue diversification of their Ig gene repertoire
through two processes, known as somatic hypermutation and class switch recombination
(CSR). Somatic hypermutation inserts point mutations into recombined VH(D)JH and VLJL
exons, thus enabling the selection of high affinity Ig variants by antigen, whereas CSR
replaces the heavy chain constant region (CH) of IgM with that of IgG, IgA, or IgE and
thereby provides new effector functions to the Ig, but preserves antigen specificity [2, 3]. A
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hallmark of CSR is the fact that actively transcribed S regions of the Ig gene become
substrates of activation-induced cytidine deaminase (AID) [4].
In general, CSR has been shown to be triggered by a primary signal derived from the
interaction between a receptor belonging to the superfamily members of TNF receptors
(TNF-R) (e.g. CD40) expressed on the surface of B cells, with a cosignal from cytokines.
Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) is a
TNF-R expressed on a fraction of B cells and binds to the TNF superfamily members B-cell
activating factor (BAFF) and a proliferation inducing ligand (APRIL). BAFF is expressed
primarily by neutrophils, monocytes, and DCs and promotes B-lymphocyte survival and
maturation, while APRIL is expressed by monocytes, macrophages, DCs, and activated T
cells [5,6]. TACI mediates isotype switching through binding of APRIL and synergizes with
CD40 and TLR9 to increase Ig production and generation of plasma cells in vitro [7, 8].
Physiologically, the T cell-dependent (TD) pathway by which B cells become activated
requires a long period of time to control rapidly replicating pathogens. To overcome this
restriction, a T cell-independent (TI) pathway involving BAFF and APRIL in extrafollicular
B cells is able to rapidly produce IgM, IgG, and IgA [9]. Innate immune cells release BAFF
and APRIL due to microbial signals arising from TLRs and then activate NF-κB by
recruiting TNF receptor-associated factors (TRAFs) through the receptor TACI [5, 10, 11].
Recently, it has been shown that BAFF and APRIL triggered CSR after recruitment of
MyD88 to the THC domain of TACI; which was identified through the generation of
E228R, T229R, S231R, and C233G substitutions by site-directed mutagenesis [12]. The toll-
IL-1 receptor (TIR) domain of TLRs and the IL-1 receptor (IL-1R) activate transcription
factors such as NF-κB through MyD88, thereby regulating innate immunity. However,
BAFF and APRIL recruit MyD88 to a THC of TACI different from the TIR domain of
TLRs. Impaired germline CH gene transcription and AID activation after TACI stimulation
were observed in both mice and humans lacking MyD88 or IL-1R-associated kinase 4
(IRAK-4), a signal transducer that binds MyD88 [12].
Mutations in TNFRSF13B, the gene encoding TACI, have been identified in 5 to 10% of
patients with common variable immunodeficiency (CVID) [13, 14]. CVID is a
heterogeneous primary immunodeficiency disease diagnosed on the basis of an impaired
ability to produce specific antibodies after vaccination or antigen exposure, markedly
reduced serum levels of IgG, IgA, and frequently IgM and exclusion of other defined causes
of antibody deficiency (e.g. Hyper IgM syndromes, X-linked lymphoproliferative disorder)
[15, 16].
In the present study, we identified and evaluated a missense mutation (S231R) predicted to
affect the highly conserved segment of the THC domain of TACI at the MyD88-binding
site, in a patient with childhood onset of CVID [17]. This patient constitutes the first CVID
case associated with a mutation in this region of TACI, prompting us to evaluate its
relevance through expression and functional studies.
Results
B cells expressing mutated TACI-S231R protein have impaired CSR processes
The mutation S231R has been reported in silico to affect the cytoplasmic conserved motif of
TACI, crucial for the induction of CSR triggered by MyD88 engagement [12]. We identified
a patient carrying this mutation and presenting CVID [17]. Blood CD19+ B-cell counts were
normal in the patient, while CD27+ switched memory B cells were very low (2% versus 14
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± 7% in age-matched controls). Virtually all CD19+ CD27+ B cells were IgM+ IgD+,
pointing to a defective in vivo CSR. These results are in accordance with the serum Ig levels
determined at onset and were typical of a CSR deficiency, with normal serum IgM levels
and profoundly low serum IgG levels with an absence of IgA. To further investigate the in
vivo mechanism of CSR in this patient, individual Sμ–Sα junctions were amplified from
genomic DNA using the previously described nested-PCR assay [18]. Despite the extremely
low level of serum IgA in the patient, the fragments could be amplified, even if the intensity
of the fragments was much lower as compared with that of a healthy donor (Fig. 1A).
However, these changes are modest compared with the few and faint bands amplified from a
DNA ligase IV gene (LIG4)-deficient patient cells, where the major double-strand break
DNA repair pathway in mammals (the non-homologous end joining machinery) is
compromised (Fig. 1A). Residual IgA switching appears to occur in our S231R patient,
although subsequent cloning and sequencing of these fragments (26 unique Sμ–Sα
sequences) showed a majority of CSR junctions representing direct switching from IgM to
IgA1, whereas in controls both IgM to IgA1 and IgM to IgA2 were observed (data not
shown). When we compared the sequences from the patient with 54 unique Sμ–Sα junctions
from a group of six healthy young individuals a slight preference of microhomology was
observed (Fig. 1A). However, no significant difference was demonstrated by the two-tailed
Student’s t-test (perfectly matched sequence homology, on average 4.44 ± 3.80 nt in the
patient versus 2.52 ± 4.45 nt in controls; p = 0.0616). This pattern of in vivo generated CSR
junctions rules out that a significant defect in the DNA repair pathway could account for the
low number of switched CD27+ B cells.
In order to test the ability to trigger TACI-dependent class switching in the patient’s B cells,
we first investigated TACI expression and APRIL-binding capacity of TACI-S231R cells.
TACI was similarly expressed in these cells than in controls (Fig. 1B and 1C) and its ability
to bind APRIL seems to be within the range observed in healthy donors (Fig. 1D). Note that
as previously shown, TACI can be expressed as a full-length protein or an alternatively
spliced form lacking exon 2, whose physiological role remains undefined [19]. To evaluate
CSR via TACI in vitro, we cultured naive B cells from the patient in the presence or absence
of a cross-linking agonistic antibody to TACI (anti-TACI) combined with IL-4 or IL-10,
which provides necessary CSR-inducing cosignals. The induction of CSR was evaluated by
analyzing the secretion of IgG by ELISA (Fig. 2A). We observed that while in healthy
donors’ cells anti-TACI or anti-TACI plus cytokines augmented the secretion of IgG after 7
days of activation, a significantly attenuated increase was shown in TACI-S231R cells. It is
interesting to note that the mother of the patient, a carrier of the same mutation [17], also
showed a reduced secretion of IgG (Fig. 2A).
Given that the engagement of TLR9 by CpG DNA has been shown to enhance the secretion
of IgG in B cells exposed to anti-TACI in the presence of activating cytokines [8, 11], we
sought to investigate its effect in these naive B cells carrying the S231R mutation. After 7
days of exposure to anti-TACI, IL-4, and CpG DNA, B cells with the S231R mutation
showed a pronounced impairment in the production of IgG (Fig. 2A). As previously shown
in some patients with CVID [20, 21], TACI-S231R exhibited an impaired response to TLR9
on enhancing B-cell Ig production. This failure to respond to TLR9, which was not rescued
by TACI ligation (Fig. 2A), raises the possibility of cross-talk between both signaling
pathways.
In an attempt to localize the precise step of the CSR defect, we checked for the occurrence
of CSR-related events by quantitative RT-PCR analysis of Iγ1-Cγ1, Iγ1-Cμ, and
activation-induced cytidine deaminase (AICDA) transcripts in lymphoblastoid B cells
obtained from the patient and her mother (Fig. 2B–D). Compared with control cells, these
cells induced less Iγ1-Cγ1 transcripts, an early marker of IgG1 CSR, in response to IL-4
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and cognate TACI ligands such as APRIL (Fig. 2B). Switched Iγ1-Cμ transcripts and
AICDA transcripts encoding AID, two hallmarks of ongoing IgG1 CSR, also showed little
or no induction after 2 days of stimulation (Fig. 2C and 2D). Similar results were obtained
through TACI engagement by APRIL or anti-TACI (Fig. 2). AICDA impairment was also
detected in patients heterozygous for either of the two most common mutations in TACI
found in CVID, C104R, and A181E (Fig. 2C). The C104R abolishes ligand binding and,
consequently, signaling [13, 14]. The A181E mutation, which is in the transmembrane
domain, does not affect ligand binding but severely impairs ligand signaling and TACI
function in vitro and in vivo [22].
Synergy between TACI and CD40 signaling fails in TACI-S231R B cells
It has been suggested that in addition to its key role in the antibody response to TI antigens,
TACI might be important for the antibody response to TD antigens [7, 8, 12]. In agreement
with this, TACI engagement enhanced transcription of AICDA by healthy donor cells
stimulated with suboptimal concentrations of anti-CD40 and IL-10 (Fig. 3A). In contrast, in
lymphoblastoid B cells from TACI-S231R patient, APRIL ligation had no detectable effect
on CD40 stimulation (Fig. 3A). It is important to note that CD40 engagement with optimal
conditions for driving CSR was preserved in patient’s cells (Fig. 3B–D), suggesting that
S231R mutation on TACI specifically impaired the cooperation between TACI and CD40
signaling to induce CSR. Germline IgE transcripts were also normally expressed after
optimal activation with CD40L and IL-4 (Fig. 3E).
Together, our results show that cells carrying the unique S231R change presented an
impaired induction of CSR by TACI and TLR9 pathways and a lack of APRIL enhancement
on CD40-driven suboptimal B-cell activation. These findings point to a defective in vivo
CSR, as in vitro activation with cognate ligands of TACI in the presence of activating
cytokines led to a poorly efficient CSR toward IgG, suggesting a defect-located upstream of
the transcription step, because even IgG germline transcripts were greatly affected (Fig. 2B
and Fig. 3B). Indeed, hallmarks of ongoing IgG1 synthesis, such as the expression of Iγ1-
Cγ1, Iγ1-Cμ, and AICDA transcripts, were induced via CD40, ruling out an intrinsic
deficiency in the CSR machinery (Fig. 3B–D). Since TACI was clearly expressed by TACI-
S231R cells (Fig. 1B and C), these results appear to be specifically linked to a failure in the
triggering of TACI signaling pathway.
B cells carrying mutated S231R-TACI protein are unable to recruit MyD88 protein
So far, our results suggest that B cells from TACI-S231R exposed to TACI and TLR9 or
TACI and CD40 ligands fail to integrate signals from these receptors to achieve optimal
antibody production. In all cases, intracellular signaling leads to the activation of NF-κB
members [23], critical for AICDA induction [24]. It has been shown that TACI induces NF-
κB activation by recruiting MyD88 to a THC domain of TACI [12]. Since the mutation
S231R resides in the THC site, we evaluated the ability of APRIL to induce recruitment of
MyD88 to TACI in unstimulated naive B cells carrying the S231R mutation, knowing that
these cells express comparable levels of MyD88 with those found in healthy donor cells
(Fig. 4A). After exposure to APRIL, confocal microscopy showed that healthy donor B cells
developed large and polarized membrane patches of colocalized TACI and MyD88 (Fig.
4B). It is important to note that the control cells chosen in this experiment did not differ
significantly from the patient’s cells in the capacity to bind APRIL (Fig. 1D). As previously
shown TRAF2, required to activate downstream signaling events, colocalizes with TACI
after stimulation of donor cells with APRIL [12] (Fig. 4B). Although in B-cell lines a
constitutive occupation of TACI by autocrine ligands complicate the demonstration of
APRIL-induced recruitment of MyD88 to the receptor, the same outcome was observed by
using lymphoblastoid B cells (Fig. 4B). However, in TACI-S231R naive B cells and
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lymphoblastoid B cells from both the patient as well as from her mother, APRIL failed to
induce such patches (Fig. 4B and data not shown). The impairment was specific of this
mutation affecting the THC domain, since in B cells from a patient heterozygous for A181E
the ability of APRIL to recruit MyD88 to TACI seems to be preserved (Fig. 4B). Previous
results on this mutant have indicated that besides a failure in signaling, TACI-A181E
properly binds to the ligand and engages in homotypic interaction [22, 25], now our findings
also exclude an impaired MyD88 clustering underlying the lack of AICDA induction in
response to TACI ligation (Fig. 2C and Fig. 4B).
Discussion
We have presented evidence in this study that B cells carrying the substitution S231R at the
MyD88-binding site of TACI abrogated TACI-driven CSR induction, as well as IgG
secretion by CpG stimulation. Furthermore, a lack of cooperation between the latter
pathways was also evidenced beside a failure of APRIL-mediated enhancement of CD40
activation in suboptimal conditions. CD40 engagement initiates TD CSR, whereas dual
TLR–BCR, TACI–BCR, or TLR–TACI engagement induces TI CSR, but also has an
important role in the early stages of TD antibody responses [3]. Whether in a TD or TI
manner, AID is required for CSR induction, and is differentially expressed depending on the
B-cell lineage and the differentiation stage. AID is clearly expressed in B cells undergoing
CSR but almost undetectable in resting mature B cells. Transcription of the AICDA gene
depends on NF-κB, and translocation to the nucleus of members of the NF-κB family is a
common event triggered by TLR9 and TACI engagement via MyD88 dimerization by TIR
domain-dependent or -independent induction, respectively [12]. In this report, we showed
that mutation S231R affecting the MyD88-binding site could prevent the association of this
adaptor molecule with TACI, and this in a specific manner since the mutation A181E lying
outside the THC domain retained the ability to interact with MyD88. Consistent with this
interpretation, ectopic expression of TACI-S231R in 293T cells decreased the binding of
MyD88 and attenuated TACI signaling via both NF-κB and AP-1 compared with that of
WT-TACI [12]. Furthermore, some patients with MyD88 or with its downstream partner,
IRAK4, deficiency showed lower IgG responses to TI antigens, and a poor induction of
AICDA and IgG CSR in B cells stimulated with APRIL or CpG DNA [12, 26]. However,
MyD88 and IRAK4 were not critical for the control of circulating IgG and IgA under
steady-state conditions [26], introducing the possibility that TACI signals through TRAF2 to
compensate for the lack of MyD88 or IRAK4. A canonical TRAF2-binding site lies
immediately downstream to the MyD88-binding site in the cytoplasmic domain of TACI. It
has been suggested that both adaptor molecules function in a cooperative manner, since only
the deletion of both MyD88- and TRAF2-binding sites completely abrogated TACI
signaling [12]. Here, we showed that naive B cells carrying TACI-S231R failed to
colocalize TACI and TRAF2 after stimulation with APRIL, suggesting that the mutation
could also prevent the association with TRAF2, probably due to the close proximity with its
binding site (spanning amino acids 240–244).
TRAF2 is also a mediator in the signaling pathway of CD40 receptor. A synergy between
TACI and CD40 ligation has been shown previously [7,8], while our data indicates that B
cells with TACI-S231R failed to integrate signals from these receptors to achieve an
enhancement of AICDA transcription as observed in B cells from healthy donors. Since
activation of CD40 with adequate concentrations of ligand showed an intact cascade of
CSR-related events, we can hypothesize that in a context of a suboptimal activation of CD40
it is necessary the cooperation with a TI pathway signaling such as TACI, to achieve an
optimal level of TRAF2 activation and subsequent CSR. This cooperation could be impaired
in our patient as we noted a failure of association between TACI and TRAF2.
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The lack of APRIL enhancement on CD40-driven B-cell activation and the clear reduction
of switched-memory B cells in our patient, allows us to speculate that this kind of
cooperation could account for the generation of CD27+ B cells in germinal centers.
Follicular activated CD4+ T cells and DCs are well-established sources of CD40 and TACI
ligands, respectively, in germinal centers [27]. Thus, it would be expected that TACI
carrying the S231R mutation would have an impaired cooperation between TACI and CD40
in a TD response.
One can also speculate that the mutation S231R rather than simply preventing an association
with the intracellular adaptor proteins, directly affects the tertiary structure of the protein
such that it impairs intracellular receptor association. This lack of association would
therefore prevent fully functional signaling of TACI. No significant difference in TACI
surface expression compared with controls was shown on peripheral B cells of the patient
[17]. TACI activation by APRIL requires ligand multimerization, suggesting a requirement
for receptor clustering or for a certain signaling threshold to be reached [28]. Activated
TACI recruits TRAFs molecules intracellularly [19, 29], which are trimeric intermediates in
the signaling pathway of numerous TNF-R family members [30]. Oligomerization of
trimeric TRAF2 is required to activate downstream signaling events [31] being necessary a
multimeric ligand to bring together more than three receptors, which will recruit to the
complex the intracellular TRAF molecules. In this regard preliminary results, as part of an
attempt to determine the structure of the cytoplasmic domain of TACI show a difference in
the apparent molecular weight of the mutated protein versus the wild type, while MS results
only evidences the gap due to the amino acid change (M. Almejun, unpublished data).
The S231R-patient evaluated in the current study is the first CVID case carrying a
substitution affecting the THC domain of TACI at the MyD88-binding site. Following the
identification of TACI as the defective gene in approximately 10% of patients with CVID, a
number of studies have questioned its causative role in the pathogenesis of the observed
humoral defects [13,14,32]. Among these, He et al. [12] have shown that TACI-ligands
elicited CSR by inducing recruitment of MyD88 to the THC cytoplasmic domain of TACI.
Our data extend these results showing that S231R mutation attenuates TACI signaling and
recruitment of MyD88, by providing cellular and biochemical evidence of an impaired CSR
in B cells obtained from a patient carrying this mutation and presenting CVID with pediatric
onset. This patient did not overtly have more severe symptoms than other patients described
with other mutations in TACI, although the clinical manifestation of such mutations is broad
and a missense mutation affecting the THC domain as observed here has not been
previously reported. In this regard, it is striking that the impairment in triggering CSR via
TACI was similarly observed in B cells from the mother of the patient, a carrier of S231R
mutation but without clinical manifestations of CVID [17]. Heterozygous TNFRSF13B
mutations have been previously associated with incomplete penetrance, therefore these
heterozygous variants could increase the risk, but would not be sufficient to cause CVID
[32]. A second event could be necessary for expressing the disease, as observed in patients
with autoimmune lymphoproliferative syndrome who carry a somatic mutation in addition to
that inherited, in another member of the TNF-R superfamily, TNFRSF6 [33]. In conclusion,
one of the greatest challenges in understanding the incomplete penetrance observed in these
families would be achieved by exposing the additional environmental or/and genetic factors
that act in concert with a heterozygous gene alteration on TNFRSF13B for the onset of
CVID.
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Materials and methods
Patient and controls
The patient was diagnosed with probable CVID according to the European Society for
Immunodeficiencies (ESID) criteria at the age of 16.1 years. Clinical and immunological
characteristics of the patient was recently published by our group [17]. Briefly, the onset
with a clinical manifestation was reported at 4.9 years of age, showing autoimmune
thrombocytopenia. This was followed by the development of recurrent upper respiratory
tract infections (sinusitis) as well as recurrent pneumonia and, later on splenomegaly and
autoimmune hemolytic anemia. At diagnosis, prior to IVIG substitution, decreased levels of
IgG and IgA with elevated IgM were reported in circulation (IgG, 33 mg/dL; IgA, <7 mg/
dL; IgM, 129 mg/dL). In order to discard hyper IgM (HIGM) syndrome, we evaluated
AICDA, CD40, uracil DNA glycosylase, and CD40L genes and no mutations were found.
The patient presented 15% (630 cells/mm3) of CD19+ B cells in total blood lymphocytes,
while the percentage of CD27−IgD+ naïve B cells was 80%, within the normal range (74 ±
10%). The proportion of CD27+IgD− switched memory B cells was highly decreased
compared to healthy donors (2% of total B cells; normal range: 14 ± 7%).
Informed written consent was obtained from the patient prior to participation, in accordance
with the Declaration of Helsinki. The research protocol was approved by the internal ethics
review board of the Hospital Garrahan.
Age-matched healthy donors included in the study provided written consent under a separate
ethics protocol for healthy donors.
Human cell isolation
PBMCs were isolated by density centrifugation over a Ficoll–Hypaque Plus (Amersham)
gradient.
Total preswitched naïve IgD+ B cells were further purified from and enriched PBMC
population as previously reported [5].
Cell cultures and reagents
Lymphoblastoid B-cell lines were generated by incubating PBMCs from the CVID patient
or healthy donors in 1 mL B95/8 supernatant for 2 h at 37°C, then adjusting to a
concentration of at least 1 × 106 cells/mL in medium containing 2 μg/mL cyclosporin A.
Cultures were performed in complete RPMI medium supplemented with 10% v/v FBS
(GIBCO). Cells were incubated with CD40L (PeproTech), 500 ng/mL; APRIL MegaLigand
(Alexis), 500 ng/mL; IL-4 (Schering-Plough), 200 U/mL, and/or IL-10 (Peprotech), 50 ng/
mL. TACI was cross-linked with 1 μg/mL mouse biotin-conjugated 11H3 mAb
(eBioscience) and anti-biotin-microbeads (Miltenyi). A similar strategy was followed to
cross-link CD40 with 1 μg/mL mouse 89 mAb (Schering-Plough). Mouse IgG1 mAb with
irrelevant-binding activity (Santa Cruz Biotechnology) was used as control. TLR9 was
activated with 5 μg/mL phosphorothioate-modified 5′-
tcgtcgttttgtcgttttgtcgtt-3′oligodeoxynucleotide-2006 (Operon Technologies).
Characterization of switch recombination junctions
Genomic DNA was purified from peripheral blood cells from patients and healthy donors
using standard methods. Amplification of Sμ–Sα from in vivo switched cells was performed
using a previously described nested PCR assay [18]. The PCR-amplified switch fragments
were gel purified (GE Healthcare), cloned into a pGEM-T vector (Invitrogen), and sequence
analysis was performed with DNA Sequencing Analysis software (PE Applied Biosystems)
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on ABI 3130 (Applied Biosystems). The CSR junctions were determined by aligning the
switch fragment sequences with the Sμ (X54713) and Sα1 (L191219) or Sα2 (AF030305).
Analysis of microhomology usage and mutation pattern at the CSR junctions was performed
as described previously [18, 34].
Immunoblotting
Proteins separated by SDS–PAGE were transferred to PVDF membranes (Millipore),
incubated with monoclonal mouse antibodies against TACI (eBiosciense), MyD88
(Millipore AB16527), or actin (Santa Cruz), and developed using secondary HRPO-
conjugated antibodies from Southern Biotech and visualized with ECL substrate (GE
Healthcare).
Ligand APRIL binding
Lymphoblastoid B-cell lines were cultured at 37°C in RPMI 1640 medium with L-glutamine
and 10% heat-inactivated FCS in triplicates. To assess binding of the ligand APRIL, B cells
were incubated with 250 ng/mL FLAG-tagged megaAPRIL (Axxora, San Diego, Calif) on
ice in the presence of heparin (1000 U/mL). A 1 mg/mL biotinanti FLAG monoclonal M2
antibody (Sigma, St Louis, Mo) was further added. The cells were washed and incubated
with streptavidin-PE. Resulting cultures were applied to a FACSCalibur (Becton Dickinson,
Mountain View, Calif) and results analyzed with FlowJo.
Laser-scanning confocal microscopy
Cells were resuspended in Cell Adhesive Solution as instructed by the manufacturer
(Crystalgen), then were applied to slides (Gold Seal Products), fixed with 1.6% v/v
paraformaldehyde and made permeable with 0.2% v/v Triton X-100 in PBS. Cells were
stained with the following unconjugated or biotin-conjugated primary polyclonal antibodies:
goat anti-MyD88 (N-19), rabbit anti-TRAF2 (C-20), mouse anti-TACI (11H3; eBioscience).
Negative controls were primary antibodies with irrelevant-binding activity and included
biotin-conjugated F(ab′)2 polyclonal antibody and unconjugated goat, mouse or rabbit
polyclonal antibodies (Santa Cruz Biotechnology). Secondary reagents included
streptavidin, Alexa Fluor 488–conjugated anti-mouse (A21202), Alexa Fluor 546–
conjugated anti-rabbit (A10040) or Alexa Fluor 647–conjugated anti-goat (A21447; all
polyclonal antibodies from Molecular Probes). Nuclei were visualized with DAPI 4′,6-
diamidine-2′-phenylindole dihydrocloride (Boehringer Mannheim). Slides were sealed with
coverslides and FluorSave reagent (Calbiochem). Fluorescent images were generated with a
Leica SP5 DMI upright confocal microscope (Wetzlar) through the acquisition of at least
three different xy planes with a 63×objective lens with numerical aperture of 1.4 (Carl Zeiss)
and with optimal z spacing (~0.016 μm). Views were constructed with maximum projection
and were exported as 30–40 tagged image file format images. AutoQuant X2 AutoDeblur
software (Media Cybernetics) was used for deconvolution of all images and restoration of
detail to data sets. Adobe Photoshop software CS3 for Macintosh, version 10 (Adobe
Systems) was used for further processing.
RT-PCR and quantitative RT-PCR
Quantification of human germline Iγ1-Cγ1 transcripts, switch Iγ1-Iγ2–Cμ circle
transcripts, AICDA transcript and ACTB, was performed by total RNA extraction from 2 or
4-days cultures with TRIzol (Invitrogen). cDNA was generated by reverse transcription with
Superscript II RT (Invitrogen). PCR primers and conditions used for standard or quantitative
RT-PCR analysis were done as reported [10, 35]. Results are normalized to ACTB mRNA
and are presented as relative expression (RE) compared with that of B cells incubated with
control antibody (Control).
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Quantification of TACI and DCLRE1C were performed by total RNA extration from
PBMCs, and cDNA was prepared using a first-strand cDNAs synthesis kit (Amersham
Biosciences, UK) according to the manufacturer’s instructions. PCR amplification of TACI
was performed using primers and conditions as previously described [36]. DCLRE1C
transcript was amplified using ART.cDNA-F 5′TCGAGGGGCAGATGGCCGAGTATC
3′and ART.cDNA-R 5′GACAGAGGTAGCTCAAGAAATCT 3′in a total volume of 40
μL and PCR conditions were: 5 min at 95°C, followed by 30 cycles of 1 min at 95°C, 1 min
at 60°C, 1 min at 72°C; the reaction was finished with a final elongation at 72°C for 10 min.
ELISA
Human IgG was measured by ELISA as described [10].
Statistical analyis
The statistical analysis of results was performed with one or two tailed Student’s t-tests
using the PRISM software (GraphPad Software Inc.).
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Abbreviations
AICDA activation-induced cytidine deaminase
AID activation-induced cytidine deaminase protein
APRIL a proliferation inducing ligand
BAFF B-cell activating factor
CSR class switch recombination
CVID common variable immunodeficiency
IRAK-4 IL-1R-associated kinase 4
TACI transmembrane activator and calcium-modulating cyclophilin ligand interactor
TD T cell-dependent
THC TACI highly conserved domain
TI T cell-independent
TIR toll-interleukin-1 receptor
TNF-R TNF receptor
TRAF TNF receptor-associated factor
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Figure 1.
Characterization of in vivo CSR junctions, TACI protein expression, and APRIL binding in
TACI-S231R patient cells. (A) PCR amplification of Sμ–Sα fragments is shown (left). Ten
PCR reactions were run in parallel using DNA from each individual. The microhomology
usage at Sμ–Sα junctions in the patient (n = 26) and controls (n = 54) is shown (right). The
proportion of switch junctions with a given size of perfectly matched short homology is
indicated by the size of the slices. (B) PCR amplification of TACI Ex1–3 transcripts and
DCLRE1C (ARTEMIS, loading control) from patient and healthy donor is shown. (C)
Immunoblot analysis of TACI protein and actin (loading control) from patient and healthy
donors is shown. (D) APRIL binding was assessed by flow cytometry. HD = Healthy
donors, P = Patient TACI-S231R. Ex1–3. FL = cDNA TACI exon 1 to 3 full lenght. Ex1–3.
ΔEx2 = cDNA TACI lacking exon 2. pTACI FL = TACI full-length protein; pTACI ΔEx2
= TACI protein lacking exon 2. Mk = molecular weight marker. Data shown are
representative of four experiments performed.
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Figure 2.
Evaluation of CSR induced by specific stimuli in B cells. (A) IgG secreted from primary
naive B cells incubated for 7 days with isotype-matched control antibody (Control), anti-
TACI, IL-4, and/or CpG DNA was evaluated by ELISA. (B and C) qRT-PCR analysis of
(B) Iγ1-Cγ1 and (C) Iγ1-Cμ in cells cultured with or without anti-TACI, APRIL, and/or
IL-4 is shown. (D) qRT-PCR analysis of AICDA in controls and TACI-deficient cells
cultured with or without anti-TACI and/or IL-10 is shown. Data are shown as the mean ±
SD of three independent experiments each performed with five samples. The statistical
analysis was performed using one-tailed Student’s t-test; ***p < 0.001; **p < 0.005; *p <
0.05. HD: Healthy donors (n = 4), P = Patient, M = Mother of the patient.
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Figure 3.
APRIL-mediated enhancement of TI and TD response. (A) AICDA expression was
evaluated after stimulation of healthy donor cells with IL-10 and different concentrations of
anti-CD40 (left). qRT-PCR analysis of AICDA in cells cultured for 2 days with APRIL and
suboptimal concentration of anti-CD40 (75 ng/mL) was also performed (right). (B–D) qRT-
PCR analysis of (B) Iγ1-Cγ1, (C) Iγ1-Cμ, and (D) AICDA in cells cultured for 2 or 4 days
with or without CpG and IL-10 or anti-CD40 (optimal concentration) and IL-4 is shown.
Data are shown as the mean ± SD of three independent experiments each performed with
two samples. The statistical analysis was performed using one-tailed Student’s t-test; ***p <
0.001; **p < 0.005; *p < 0.05. P = Patient, HD = Healthy donors (n = 3). (E) The expression
of Iμ-Cε, AICDA mRNA was measured by RT-PCR in B cells stimulated for 2 days with
CD40L (optimal concentration) and IL-4 (top). Semiquantitative RT-PCR analysis of the
expression of Iμ-Cεafter 2 days of stimulation was also performed (bottom). Data shown are
representative of three experiments performed. P = patient, HD = healthy donors, Mk =
molecular weight marker.
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Figure 4.
Recruitment of MyD88 and TRAF2 after APRIL ligation. (A) Immunoblot analysis of
MyD88 protein and actin (loading control) from patient and healthy donor is shown. (B)
Confocal microscopy of cells exposed for 15 min to medium or APRIL with staining for
TACI (green), TRAF2 (red), and MyD88 (gray) is shown. Original magnification 63×.
Arrowheads indicate colocalization of TACI, MyD88, and TRAF2 proteins. Data shown are
representative of three independent experiments performed for each sample. P = patient, HD
= healthy donors, S231R = cells from patient carrying TACI-S231R mutation, A181E =
cells from patient carrying TACI-A181E mutation.
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